Gottlieb's Short Tenure Will Be Felt Long After He Leaves US FDA

Commissioner Scott Gottlieb will leave FDA less than two years after his confirmation, but will exit with a substantial list of accomplishments for industry and patients.

US FDA Commissioner Scott Gottlieb, one of the most popular and visible commissioners in decades, will end his tenure as head of FDA in about a month, having moved the agency in new directions while also advancing high-profile policies.

Gottlieb amassed a legacy that includes new approaches to drug pricing and opioid policy, as well as record generic and novel drug approval

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Leo Roars To A Profit In Q1 As Adbry Grows In US

15 May 2025

• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Lundbeck Lifted By Leap In Migraine Therapy Sales

14 May 2025

• By Kevin Grogan

Vyepti revenues rise by nearly 70% in the first quarter.

Strong Showing For Bayer’s Pharma Business In Uncertain Times

13 May 2025

• By Kevin Grogan

As CEO Anderson backs high prices for innovative drugs in Europe

Sustainability Key To ABL Bio’s Journey From ‘Good To Great’

13 May 2025

• By Jung Won Shin

Helped by a recent major platform deal with GSK, South Korea's ABL Bio is aiming to build its R&D portfolio with an eye on being acquired in the future. CEO Sang Hoon Lee sat down with Scrip to explain the venture's journey so far and its ambitious roadmap.

Most Favored Nation Policy ‘Lazy, Misguided,’ But US Price Reforms Politically ‘Inevitable’

15 May 2025

• By Cathy Kelly

Policy experts and pharma executives react to President Trump’s executive order on “equalizing” drug prices between the US and comparable nations at the ISPOR 2025 conference.